In:
Cancer, Wiley, Vol. 123, No. 14 ( 2017-07-15), p. 2688-2697
Abstract:
In this multicenter, cooperative‐group, 2‐stage, single‐arm clinical trial, 7 of 73 evaluable patients (9.6%) with mucosal, acral, vulvovaginal, or chronically sun‐damaged melanoma achieved a partial response (wild‐type KIT, 3 of 42; KIT mutation, 4 of 25; and unknown KIT status, 0 of 6). The dasatinib response rate among KIT‐mutant melanoma patients is lower than anticipated.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v123.14
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink